{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:42:12Z","timestamp":1791312132417,"version":"4.3.1"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.neurobiolaging.2011.09.006","type":"journal-article","created":{"date-parts":[[2011,11,10]],"date-time":"2011-11-10T09:29:35Z","timestamp":1320917375000},"page":"S20-S36","source":"Crossref","is-referenced-by-count":106,"special_numbering":"S1","title":["Amyloid imaging as a biomarker for cerebral \u03b2-amyloidosis and risk prediction for Alzheimer dementia"],"prefix":"10.1016","volume":"32","author":[{"given":"William E.","family":"Klunk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4 suppl","key":"10.1016\/j.neurobiolaging.2011.09.006_bib1","first-page":"S1","article-title":"The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease","volume":"18","year":"1997","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","article-title":"Frequent amyloid deposition without significant cognitive impairment among the elderly","volume":"65","author":"Aizenstein","year":"2008","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1001\/archneur.64.3.431","article-title":"Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report","volume":"64","author":"Bacskai","year":"2007","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","article-title":"CSF markers for incipient Alzheimer's disease","volume":"2","author":"Blennow","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1212\/WNL.0b013e3181c918b5","article-title":"Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia","volume":"74","author":"Bourgeat","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological staging of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib7","doi-asserted-by":"crossref","first-page":"e6294","DOI":"10.1371\/journal.pone.0006294","article-title":"Longitudinal study of CSF biomarkers in patients with Alzheimer's disease","volume":"4","author":"Buchhave","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1212\/WNL.0b013e3181c7da8e","article-title":"In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia","volume":"74","author":"Burack","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WAD.0b013e31816c92bf","article-title":"Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B","volume":"22","author":"Butters","year":"2008","journal-title":"Alzheimer Dis. Assoc. Disord"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib10","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archneurol.2009.279","article-title":"Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report","volume":"66","author":"Cairns","year":"2009","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib13","doi-asserted-by":"crossref","first-page":"14770","DOI":"10.1523\/JNEUROSCI.3669-09.2009","article-title":"Basal cerebral metabolism may modulate the cognitive effects of A\u03b2 in mild cognitive impairment: an example of brain reserve","volume":"29","author":"Cohen","year":"2009","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.neurobiolaging.2010.03.016","article-title":"Integrating ADNI results into Alzheimer's disease drug development programs","volume":"31","author":"Cummings","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib15","article-title":"Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo","author":"Darreh-Shori","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/0891988710363715","article-title":"Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls","volume":"23","author":"Devanand","year":"2010","journal-title":"J. Geriatr. Psychiatry Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib17","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.0b013e3181a2e8d0","article-title":"Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease","volume":"72","author":"Drzezga","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.neuroimage.2007.09.020","article-title":"Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease","volume":"39","author":"Drzezga","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/01.wnl.0000244749.20056.d4","article-title":"Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study","volume":"68","author":"Edison","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib21","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/jnnp.2007.127878","article-title":"Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography","volume":"79","author":"Edison","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib22","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/brain\/awl178","article-title":"Two-year follow-up of amyloid deposition in patients with Alzheimer's disease","volume":"129","author":"Engler","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/emmm.200900048","article-title":"Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease","volume":"1","author":"Fagan","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","article-title":"Cerebrospinal fluid tau\/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults","volume":"64","author":"Fagan","year":"2007","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/156720510790274446","article-title":"High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr","volume":"7","author":"Forsberg","year":"2010","journal-title":"Alzheimer Res"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib27","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","article-title":"PET imaging of amyloid deposition in patients with mild cognitive impairment","author":"Forsberg","year":"2008","journal-title":"Neurobiol. Aging 29"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib28","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.neuroimage.2008.07.053","article-title":"Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging","volume":"43","author":"Fripp","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2010.03.011","article-title":"Cognition, glucose metabolism and amyloid burden in Alzheimer's disease","author":"Furst","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1212\/01.WNL.0000132523.27540.81","article-title":"Mild cognitive impairment, amnestic type: an epidemiologic study","volume":"63","author":"Ganguli","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib31","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1212\/01.wnl.0000326146.60732.d6","article-title":"Imaging amyloid deposition in Lewy body diseases","volume":"71","author":"Gomperts","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.21528","article-title":"Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B","volume":"64","author":"Greenberg","year":"2008","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib33","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.neurobiolaging.2008.01.016","article-title":"Clinical severity of Alzheimer's disease is associated with PIB uptake in PET","volume":"30","author":"Grimmer","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib34","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.biopsych.2009.01.027","article-title":"Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid","volume":"65","author":"Grimmer","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib35","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.biopsych.2010.05.013","article-title":"Progression of cerebral amyloid load is associated with the apolipoprotein E \u03b54 genotype in Alzheimer's disease","volume":"68","author":"Grimmer","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","article-title":"Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study","volume":"5","author":"Hansson","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib37","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.1523\/JNEUROSCI.3189-09.2009","article-title":"Disruption of functional connectivity in clinically normal older adults harboring amyloid burden","volume":"29","author":"Hedden","year":"2009","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib38","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib40","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/awm336","article-title":"11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment","volume":"131","author":"Jack","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib41","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Alzheimer's Disease Neuroimaging Initiative","volume":"132","author":"Jack","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jalz.2010.03.003","article-title":"The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core","volume":"6","author":"Jagust","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib43","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","article-title":"Alzheimer's Disease Neuroimaging Initiative","volume":"73","author":"Jagust","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.parkreldis.2007.07.010","article-title":"[(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results","volume":"14","author":"Johansson","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib45","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1471-4159.2010.06812.x","article-title":"Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand","volume":"114","author":"Jureus","year":"2010","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00415-009-5377-y","article-title":"Posterior cortical atrophy with [11C] Pittsburgh compound B accumulation in the primary visual cortex","volume":"257","author":"Kambe","year":"2010","journal-title":"J. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib47","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1212\/01.wnl.0000240117.55680.0a","article-title":"Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease","volume":"67","author":"Kemppainen","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib48","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1212\/01.wnl.0000260969.94695.56","article-title":"PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment","volume":"68","author":"Kemppainen","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib50","doi-asserted-by":"crossref","first-page":"10598","DOI":"10.1523\/JNEUROSCI.2990-05.2005","article-title":"Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain","volume":"25","author":"Klunk","year":"2005","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib51","doi-asserted-by":"crossref","first-page":"10598","DOI":"10.1523\/JNEUROSCI.2990-05.2005","article-title":"Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain","volume":"25","author":"Klunk","year":"2005","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib52","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1093\/brain\/awl281","article-title":"Two-year follow-up of amyloid deposition in patients with Alzheimer's disease","volume":"129","author":"Klunk","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib53","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.56.9.1143","article-title":"Practice parameter: diagnosis of dementia (an evidence-based review)","volume":"56","author":"Knopman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib54","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000163927","article-title":"PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment","volume":"26","author":"Koivunen","year":"2008","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib55","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1212\/01.WNL.0000034176.07159.F8","article-title":"Incidence and outcome of mild cognitive impairment in a population-based prospective cohort","volume":"59","author":"Larrieu","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib56","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archneur.65.10.noc80013","article-title":"Assessment of \u03b2-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B","volume":"65","author":"Leinonen","year":"2008","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib57","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00259-008-0833-y","article-title":"Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease","volume":"35","author":"Li","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib58","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1093\/brain\/awm191","article-title":"PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis","volume":"130","author":"Lockhart","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib59","first-page":"1959","article-title":"Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis","volume":"46","author":"Lopresti","year":"2005","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib60","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.108.058529","article-title":"Comparison of 18F-FDG and PiB PET in cognitive impairment","volume":"50","author":"Lowe","year":"2009","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib61","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.nbd.2008.12.008","article-title":"Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics","volume":"34","author":"Maetzler","year":"2009","journal-title":"Neurobiol. Dis"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib62","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.neuroimage.2007.09.072","article-title":"[11C]PIB binding in Parkinson's disease dementia","volume":"39","author":"Maetzler","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib63","first-page":"506","article-title":"Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease","volume":"338","author":"Mayeux","year":"1998","journal-title":"Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J. Med"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib64","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I\u2013FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib65","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1212\/WNL.53.5.902","article-title":"Report of the second dementia with Lewy body international workshop: diagnosis and treatment","volume":"53","author":"McKeith","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib66","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib67","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2967\/jnumed.108.057612","article-title":"Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements","volume":"50","author":"McNamee","year":"2009","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib68","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1212\/WNL.0b013e3181c0d427","article-title":"Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum","volume":"73","author":"Migliaccio","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib69","first-page":"479","article-title":"The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)","volume":"41","author":"Mirra","year":"1991","journal-title":"Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib70","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1600-0447.2008.01326.x","article-title":"Rate of progression of mild cognitive impairment to dementia\u2014meta-analysis of 41 robust inception cohort studies","volume":"119","author":"Mitchell","year":"2009","journal-title":"Acta Psychiatr. Scand"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jns.2009.12.014","article-title":"Pittsburgh compound B binding in poststroke dementia","volume":"290","author":"Mok","year":"2010","journal-title":"J. Neurol. Sci"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib72","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awn320","article-title":"Alzheimer's Disease Neuroimaging Initiative","volume":"132","author":"Mormino","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib73","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib74","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archneurol.2009.269","article-title":"Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease","volume":"66","author":"Morris","year":"2009","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.21843","article-title":"APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging","volume":"67","author":"Morris","year":"2010","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib76","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","article-title":"Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline","volume":"283","author":"N\u00e4slund","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib77","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","article-title":"Phase 1 study of the Pittsburgh Compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease","volume":"50","author":"Nelissen","year":"2009","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib78","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2967\/jnumed.106.037762","article-title":"Visual assessment versus quantitative assessment of 11C\u2013PIB PET and 18F-FDG PET for detection of Alzheimer's disease","volume":"48","author":"Ng","year":"2007","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib79","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1212\/01.wnl.0000338622.27876.0d","article-title":"Microglial activation and amyloid deposition in mild cognitive impairment: a PET study","volume":"72","author":"Okello","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib80","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","article-title":"Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C\u2013PIB PET study","volume":"73","author":"Okello","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib81","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib82","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/brain\/awm238","article-title":"\u03b2-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease","volume":"130","author":"Pike","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib83","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/sj.jcbfm.9600146","article-title":"Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B","volume":"25","author":"Price","year":"2005","journal-title":"J. Cereb. Blood Flow Metab"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib84","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/brain\/awp326","article-title":"Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden","volume":"133","author":"Rabinovici","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib85","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1212\/01.wnl.0000259035.98480.ed","article-title":"11C\u2013PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration","volume":"68","author":"Rabinovici","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib86","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ana.21451","article-title":"Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia","volume":"64","author":"Rabinovici","year":"2008","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib87","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jneumeth.2008.05.005","article-title":"Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B","volume":"172","author":"Raji","year":"2008","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib88","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.0900345106","article-title":"Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease","volume":"106","author":"Reiman","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib89","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ana.21904","article-title":"Cognition, reserve, and amyloid deposition in normal aging","volume":"67","author":"Rentz","year":"2010","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib90","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/WNL.0b013e3181d3e3e9","article-title":"Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB","volume":"74","author":"Resnick","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib91","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib92","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1212\/WNL.56.1.37","article-title":"Classification criteria for mild cognitive impairment: a population-based validation study","volume":"56","author":"Ritchie","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib93","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1212\/WNL.0b013e3181e620f4","article-title":"Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept","volume":"75","author":"Roe","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib94","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neurobiolaging.2009.02.011","article-title":"PIB binding in aged primate brain: Enrichment of high-affinity sites in humans with Alzheimer's disease","volume":"32","author":"Rosen","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib95","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","article-title":"Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism","volume":"7","author":"Rowe","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib96","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib97","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","article-title":"Imaging beta-amyloid burden in aging and dementia","volume":"68","author":"Rowe","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib98","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/WNL.0b013e3181bacf1b","article-title":"Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls","volume":"73","author":"Scheinin","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib99","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.neuroimage.2008.07.022","article-title":"Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease","volume":"43","author":"Shin","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib100","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMoa054625","article-title":"PET of brain amyloid and tau in mild cognitive impairment","volume":"355","author":"Small","year":"2006","journal-title":"N Engl J. Med"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib101","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/archneurol.2010.357","article-title":"In vivo fibrillar \u03b2-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults","volume":"68","author":"Sojkova","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib102","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/archneurol.2009.272","article-title":"Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition","volume":"66","author":"Storandt","year":"2009","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib103","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00259-010-1382-8","article-title":"Visual assessment of [(11)C]PIB PET in patients with cognitive impairment","volume":"37","author":"Suotunen","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib104","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3233\/JAD-2008-15301","article-title":"Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation","volume":"15","author":"Tenovuo","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1471-4159.2009.05996.x","article-title":"Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies","volume":"109","author":"Thompson","year":"2009","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib106","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/jnnp.2009.194779","article-title":"Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images","volume":"81","author":"Tolboom","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib107","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.2967\/jnumed.109.064360","article-title":"Relationship of cerebrospinal fluid markers to 11C-PiB and 18F\u2013FDDNP binding","volume":"50","author":"Tolboom","year":"2009","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib108","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1212\/WNL.0b013e3181c679cc","article-title":"Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment","volume":"73","author":"Tolboom","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib109","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00259-009-1129-6","article-title":"Test\u2013retest variability of quantitative [11C]PIB studies in Alzheimer's disease","volume":"36","author":"Tolboom","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2967\/jnumed.108.056499","article-title":"Detection of Alzheimer Pathology In Vivo Using Both 11C\u2013PIB and 18F\u2013FDDNP PET","volume":"50","author":"Tolboom","year":"2009","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib111","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00259-005-1780-5","article-title":"PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease","volume":"32","author":"Toyama","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib112","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/jnnp.2008.171496","article-title":"11C-PiB PET studies in typical sporadic Creutzfeldt\u2013Jakob disease","volume":"80","author":"Villemagne","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib113","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.neuropsychologia.2008.02.008","article-title":"Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease","volume":"46","author":"Villemagne","year":"2008","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib114","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1212\/01.wnl.0000238517.59286.c5","article-title":"Ten-year risk of dementia in subjects with mild cognitive impairment","volume":"67","author":"Visser","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jalz.2010.03.007","article-title":"Alzheimer's Disease Neuroimaging Initiative","volume":"6","author":"Weiner","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib116","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/ana.21598","article-title":"Amyloid imaging in mild cognitive impairment subtypes","volume":"65","author":"Wolk","year":"2009","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib117","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","article-title":"In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)","volume":"51","author":"Wong","year":"2010","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.neurobiolaging.2011.09.006_bib118","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.neuroimage.2007.03.004","article-title":"Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease","volume":"36","author":"Zhou","year":"2007","journal-title":"Neuroimage"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458011003435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458011003435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T16:14:03Z","timestamp":1713111243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458011003435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":116,"alternative-id":["S0197458011003435"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.09.006","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}